Evaluation of AOC 1001's Therapeutic Potential in Myotonic Dystrophy Type 1 Patients.

Published Date: 16 Nov 2023

The chief medical officer of Avidity, Steve Hughes, MD, offered insight into the recently released positive phase 1/2 and OLE data assessing AOC 1001, an experimental antisense oligonucleotide, in individuals suffering from myotonic dystrophy type 1.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot